WO2009028387A1 - プロテアーゼ阻害剤耐性を有する癌の治療薬 - Google Patents
プロテアーゼ阻害剤耐性を有する癌の治療薬 Download PDFInfo
- Publication number
- WO2009028387A1 WO2009028387A1 PCT/JP2008/064887 JP2008064887W WO2009028387A1 WO 2009028387 A1 WO2009028387 A1 WO 2009028387A1 JP 2008064887 W JP2008064887 W JP 2008064887W WO 2009028387 A1 WO2009028387 A1 WO 2009028387A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lower alkyl
- resistance
- therapeutic agent
- substituted lower
- represents hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
ヒートショック蛋白質90(Hsp90)ファミリー蛋白質阻害剤として、式(I)
[式中、nは1~5の整数を表し、
R1は置換もしくは非置換の低級アルキル、CONR7R8(式中、R7及びR8は同一または異なって、水素原子、置換もしくは非置換の低級アルキル等を表す)等を表し、
R2は置換もしくは非置換のアリール等を表し、
R3及びR5は同一または異なって、水素原子、置換もしくは非置換の低級アルキル等を表し、
R4は水素原子等を表し、
R6は水素原子、ハロゲン、置換もしくは非置換の低級アルキル等を表す]で表されるベンゾイル化合物またはその薬学的に許容される塩を含有する、プロテアーゼ阻害剤耐性を有する癌の治療薬等を提供する。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08792608A EP2184073A4 (en) | 2007-08-24 | 2008-08-21 | AGAINST PROTEASE HEMMER RESISTANT CANCER THERAPEUTICS |
JP2009530067A JPWO2009028387A1 (ja) | 2007-08-24 | 2008-08-21 | プロテアーゼ阻害剤耐性を有する癌の治療薬 |
US12/674,230 US20110112099A1 (en) | 2007-08-24 | 2008-08-21 | Therapeutic agent for cancer resistant to protease inhibitor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007217880 | 2007-08-24 | ||
JP2007-217880 | 2007-08-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009028387A1 true WO2009028387A1 (ja) | 2009-03-05 |
Family
ID=40387109
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/064887 WO2009028387A1 (ja) | 2007-08-24 | 2008-08-21 | プロテアーゼ阻害剤耐性を有する癌の治療薬 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20110112099A1 (ja) |
EP (1) | EP2184073A4 (ja) |
JP (1) | JPWO2009028387A1 (ja) |
WO (1) | WO2009028387A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8846030B2 (en) * | 1999-06-08 | 2014-09-30 | University Of Iowa Research Foundation | Compounds and methods to enhance rAAV transduction |
US11684679B2 (en) | 2016-03-07 | 2023-06-27 | University Of Iowa Research Foundation | AAV-mediated expression using a synthetic promoter and enhancer |
US11702672B2 (en) | 2016-02-08 | 2023-07-18 | University Of Iowa Research Foundation | Methods to produce chimeric adeno-associated virus/bocavirus parvovirus |
US11999965B2 (en) | 2021-09-09 | 2024-06-04 | University Of Iowa Research Foundation | Bocaparvovirus small noncoding RNA and uses thereof |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2680161A1 (en) * | 2007-03-05 | 2008-09-12 | Kyowa Hakko Kirin Co., Ltd. | Pharmaceutical composition |
EP3512602B1 (en) | 2016-09-16 | 2024-03-27 | HSF Pharmaceuticals | Inhibitors of heat shock factors (hsf) and uses thereof |
CN109879921B (zh) * | 2019-03-26 | 2022-03-29 | 安徽中医药大学 | 从知母中分离的具有抗肿瘤活性的化合物及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005000778A1 (ja) * | 2003-06-27 | 2005-01-06 | Kyowa Hakko Kogyo Co., Ltd. | Hsp90ファミリー蛋白質阻害剤 |
WO2005063222A1 (ja) * | 2003-12-26 | 2005-07-14 | Kyowa Hakko Kogyo Co., Ltd. | Hsp90ファミリー蛋白質阻害剤 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2006088193A1 (ja) * | 2005-02-21 | 2008-07-03 | 協和醗酵工業株式会社 | 抗腫瘍剤 |
-
2008
- 2008-08-21 WO PCT/JP2008/064887 patent/WO2009028387A1/ja active Application Filing
- 2008-08-21 US US12/674,230 patent/US20110112099A1/en not_active Abandoned
- 2008-08-21 EP EP08792608A patent/EP2184073A4/en not_active Withdrawn
- 2008-08-21 JP JP2009530067A patent/JPWO2009028387A1/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005000778A1 (ja) * | 2003-06-27 | 2005-01-06 | Kyowa Hakko Kogyo Co., Ltd. | Hsp90ファミリー蛋白質阻害剤 |
WO2005063222A1 (ja) * | 2003-12-26 | 2005-07-14 | Kyowa Hakko Kogyo Co., Ltd. | Hsp90ファミリー蛋白質阻害剤 |
Non-Patent Citations (28)
Title |
---|
"Blood", vol. 108, 2006 |
BLOOD, vol. 100, 2002, pages 3041 - 3044 |
BLOOD, vol. 106, 2005 |
BLOOD, vol. 108, 2006 |
BLOOD, vol. 96, 2000, pages 2284 - 2291 |
BLOOD, vol. 99, 2002, pages 3472 - 3475 |
CANCER RESEARCH, vol. 62, 2002, pages 4996 - 5000 |
CANCER RESEARCH, vol. 65, 2005, pages 6401 - 6408 |
CANCER RESEARCH, vol. 66, 2006, pages 9153 - 9161 |
CLINICAL CANCER RESEARCH, vol. 12, 2003, pages 2622 - 2627 |
CLINICAL CANCER RESEARCH, vol. 12, 2007, pages 6494 - 6501 |
CURRENT MEDICINAL CHEMISTRY, vol. 14, 2007, pages 223 - 232 |
IMMUNOLOGY LETTERS, vol. 104, 2006, pages 146 - 155 |
INT. J. CANCER, vol. 49, pages 650 - 655 |
JOURNAL OF CLINICAL ONCOLOGY, vol. 17, 1999, pages 2639 - 2648 |
JOURNAL OF CLINICAL ONCOLOGY, vol. 21, 2003, pages 4342 - 4349 |
JOURNAL OF CLINICAL ONCOLOGY, vol. 24, 2006, pages 4764 - 4774 |
LEUKEMIA, vol. 17, 2003, pages 829 - 838 |
MITSIADES C.S. ET AL.: "Antimyeloma activity of heat shock protein-90 inhibition", BLOOD, vol. 107, no. 3, 2006, pages 1029 - 1100, XP008130012 * |
MITSIADES N. ET AL.: "Molecular sequelae of proteasome inhibition in human multiple myeloma cells", PROC.NATL.ACAD.SCI. U.S.A., vol. 99, no. 22, 2002, pages 14374 - 14379, XP008130013 * |
NEW ENGLAND JOURNAL OF MEDICINE, vol. 344, 2001, pages 1031 - 1037 |
NEW ENGLAND JOURNAL OF MEDICINE, vol. 344, 2001, pages 1084 - 1086 |
NEW ENGLAND JOURNAL OF MEDICINE, vol. 344, 2001, pages 783 - 792 |
NEW ENGLAND JOURNAL OF MEDICINE, vol. 348, 2003, pages 2609 - 2617 |
NEW ENGLAND JOURNAL OF MEDICINE, vol. 352, 2005, pages 786 - 792 |
SCIENCE, vol. 235, 1987, pages 177 - 182 |
See also references of EP2184073A4 |
SHRINGARPURE R. ET AL.: "Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib", BRITISH JOURNAL OF HAEMATOLOGY, vol. 134, no. 2, 2006, pages 145 - 156, XP009129391 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8846030B2 (en) * | 1999-06-08 | 2014-09-30 | University Of Iowa Research Foundation | Compounds and methods to enhance rAAV transduction |
US11702672B2 (en) | 2016-02-08 | 2023-07-18 | University Of Iowa Research Foundation | Methods to produce chimeric adeno-associated virus/bocavirus parvovirus |
US11684679B2 (en) | 2016-03-07 | 2023-06-27 | University Of Iowa Research Foundation | AAV-mediated expression using a synthetic promoter and enhancer |
US11999965B2 (en) | 2021-09-09 | 2024-06-04 | University Of Iowa Research Foundation | Bocaparvovirus small noncoding RNA and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
EP2184073A1 (en) | 2010-05-12 |
US20110112099A1 (en) | 2011-05-12 |
EP2184073A4 (en) | 2010-10-20 |
JPWO2009028387A1 (ja) | 2010-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200612958A (en) | Substituted imidazole derivatives | |
WO2008108386A1 (ja) | 医薬組成物 | |
MY148703A (en) | Polycyclic cinnamide derivatives | |
WO2005110410A3 (en) | Kinase inhibitors as therapeutic agents | |
MX2007004699A (es) | Derivados de indol y bencimidazol. | |
TW200728307A (en) | Novel spirochromanone derivatives | |
HRP20080493T3 (en) | Substituted quinoline derivatives as mitotic kinesin inhibitors | |
MX2009011579A (es) | Pirimidinonas como moduladores de caseina cinasa ii (ck2). | |
TR201900306T4 (tr) | Mek inhibitörlerini kullanma yöntemleri. | |
MY150507A (en) | Polycyclic compound | |
UA94606C2 (ru) | Производные тиоксантина, композиция, которая их содержит, и их применение в терапии | |
ATE553106T1 (de) | Heteroarylpyrrolopyridinone als kinaseinhibitoren | |
DE60328010D1 (de) | Heterocyclische verbindungen | |
MY147188A (en) | Substituted imidazole compounds as ksp inhibitors | |
MX2009004920A (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1. | |
DE60333746D1 (de) | Thienylverbindungen | |
MX2009007260A (es) | Derivados de imidazol como inhibidores de proteina de huso de cinesina (eg-5). | |
MX2009008756A (es) | Compuesto macrociclico. | |
WO2009028387A1 (ja) | プロテアーゼ阻害剤耐性を有する癌の治療薬 | |
TW200728298A (en) | Thiophene compounds and thrombopoietin receptor activators | |
EA200900631A1 (ru) | Замещённые пиразолы и триазолы, как ингибиторы кбв (кинезин-белок веретена) | |
TW200744575A (en) | Methods of treating epileptogenesis | |
TW200738697A (en) | Benzimidazole derivatives as 5-HT6,5-HT24 | |
MX2007002600A (es) | Mercaptoamidas como inhibidores de la histona deacetilasa. | |
WO2008110690A3 (fr) | Nouveaux derives indoliques, leurs procedes de preparation et leurs utilisations notamment en tant qu'antibacteriens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08792608 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009530067 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12674230 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008792608 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |